Oxford Immune Algorithmics (OIA), the award-winning A.I. company that specialises in rapid at-home testing for immune health monitoring, and the creators of Algocyte, know something about legacy. Legacy is an idea that begins in the past but endures into the future. To build a legacy requires vision, driven by courage, endurance, and a laser-sharp focus to deliver on a dream, forging it into reality. Legacy also has much to do with the integrity of an idea that will endure and become a reality.
When most people think of the epitome of science-fiction, Gene Roddenberry’s creation, ‘Star Trek’ comes to mind. His vision of a galaxy and his optimism for the future were palpable and inspired many creators. For generations, the Star Trek franchise has been as relevant as when it first aired in 1966, and still serves as a benchmark of what true vision and excellence could be. The motto, ‘to boldly go where no one has gone before” has inspired countless creators who are pushing the limits of what is possible while solving enormous global challenges.
Roddenberry’s genius lay in introducing technology that would benefit all of humanity while tearing down boundaries such as inequality, private ownership of land, and unchecked power. His ideas forced us to rethink who has the right to live and prosper and who deserves to benefit from technological advances. Underlying his vision was a belief in the universality of technology, as an integral part of society, of benefit to all. His innovations were tele-transportation, warp speed, where aircraft travelled faster than the speed of light, and teleportation. But, perhaps the most inspiring innovation was the tricorder, the non-invasive hand-held device that monitored objects, including the human body.
For the founders of Oxford Immune Algorithmics (OIA), the tricorder was also the catalyst for the company and its AI-driven solution, Algocyte. Algocyte represents one of the first devices created to utilise the power of AI for personalised monitoring of the immune system to detect, prevent and ultimately end disease. The AI-driven solution, Algocyte, thinks like a scientist, and goes beyond current medical capabilities. And, for OIA’s founders, having Commander Riker introduce Algocyte is the culmination of a vision long in the making.
At the core of an enduring idea is ultimately hope. Hope for humanity, for a more sustainable future, and hope that new technologies can help solve some of our biggest challenges. Oxford Immune Algorithmics has created and delivered on its promise of more precise and individualised healthcare and is creating a legacy of more affordable, precise, and personalised care.
Oxford Immune Algorithmics (OIA) is an award-winning Bio and MedTech company incubated by the University of Oxford with a mission to rid the world of preventable diseases. It operates multi-nationally to build technology that moves healthcare away.